UPDATE

Alliance awards three-product commercial supply contract to SCM Pharma

By Natalie Morrison

- Last updated on GMT

Related tags: Scm pharma

SCM Pharma has inked a commercial supply contract with Alliance for the sterile manufacturing of three of its products.

The UK-based development and contract manufacturing organisation (CDMO) will take on the filling, packaging and testing of three Alliance injectable products.

They include Edrophonium for the diagnosis of auto immune disease myasthenia gravis, antituberculosis compound Isoniazid, and Pentagastrin, used to test medullary carcinoma of the thyroid.

Alliance says it was SCM’s capabilities to support speciality pharmaceutical firms with the supply of niche, and often low yield products that won them the contract.

David Yau, production, technical & quality director at Alliance, said: “We were impressed by SCM Pharma’s track record and are confident in their ability to deliver these three products.”

Pastures new

SCM now hopes the new deal will help them to gain a stronger footing in the world of CMDO, according to the head of communications Raman Sehgal.

He told Outsourcing-Pharma: “For the business it’s another commercial contract we’ve got under our belt.

“From a financial stand point, this is very good for sustainability in terms of having a constant stream of work from a large-scale pharmaceutical company.

“There’s also the possibility that Alliance will want us to look at manufacturing more of their products at a later stage.

“Finally, it’s good for generating business for us in the sense that it let’s the rest of the industry know that this is who we are and that we can handle novel, difficult and even dangerous products.

Graham Dotchin, commercial director at SCM Pharma, added: “We are delighted to be working with the team at Alliance Pharma and supporting them in the supply of these three sterile products​.

“We hope this is the start of a long term relationship with Alliance Pharma and look forward to meeting their product supply requirements.”

Related news

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q² Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Related suppliers

Follow us

Products

View more

Webinars